Analyst Price Targets — SUPN
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 25, 2026 2:19 pm | — | Craig-Hallum | $65.00 | $57.58 | StreetInsider | Supernus Pharmaceuticals (SUPN) PT Raised to $65 at TD Cowen |
| December 19, 2025 12:50 pm | Annabel Samimy | Stifel Nicolaus | $55.00 | $49.28 | TheFly | Supernus price target raised to $55 from $50 at Stifel |
| October 8, 2025 11:34 pm | — | Piper Sandler | $65.00 | $48.00 | TheFly | Supernus upgraded to Overweight from Neutral at Piper Sandler |
| September 30, 2025 12:42 pm | — | Cantor Fitzgerald | $63.00 | $47.41 | TheFly | Supernus price target raised to $63 from $46 at Cantor Fitzgerald |
| August 29, 2025 10:36 am | — | Piper Sandler | $40.00 | $45.12 | TheFly | Supernus price target raised to $40 from $36 at Piper Sandler |
| July 29, 2025 8:08 pm | — | Cantor Fitzgerald | $42.00 | $33.45 | TheFly | Supernus upgraded to Overweight from Neutral at Cantor Fitzgerald |
| September 11, 2024 4:55 am | David Amsellem | Piper Sandler | $36.00 | $33.49 | TheFly | Piper downgrades Supernus to Neutral on slower Qelbree growth |
| May 24, 2024 7:28 am | David Amsellem | Piper Sandler | $41.00 | $27.85 | StreetInsider | Piper Sandler Reiterates Overweight Rating on Supernus Pharmaceuticals (SUPN) |
| April 8, 2024 10:10 am | Irene Buhalo | Jefferies | $40.00 | $32.27 | StreetInsider | Jefferies on Supernus (SUPN): 'We expect a -5-10% stock reaction after the FDA's rejection of SPN-830' |
| April 8, 2024 10:09 am | Annabel Samimy | Stifel Nicolaus | $38.00 | $32.27 | StreetInsider | Stifel on Supernus Pharmaceuticals (SUPN): 'SPN-830 Approval Delayed Again, but Near-Term Impact Relatively Minor' |
Latest News for SUPN
Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN). In a filing disclosed on April 07th, the Representative disclosed that they had bought between $1,001 and $15,000 in Supernus Pharmaceuticals stock on March 3rd. The trade occurred in the Representative's "150 MAIN STREET TRUST > BANK OF AMERICA" account. Representative
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN - Get Free Report)'s share price crossed above its two hundred day moving average during trading on Tuesday. The stock has a two hundred day moving average of $49.66 and traded as high as $51.06. Supernus Pharmaceuticals shares last traded at $50.96, with a volume of 873,941 shares. Analysts Set
JPMorgan Chase and Co. trimmed its holdings in shares of Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) by 45.6% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 171,285 shares of the specialty pharmaceutical company's stock after selling 143,816 shares during the period. JPMorgan Chase
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN - Get Free Report) has received a consensus rating of "Hold" from the seven brokerages that are currently covering the company, Marketbeat reports. Two research analysts have rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating on the company. The
A Supernus Pharmaceuticals executive reported the sale of 107,250 Common Stock shares over three days for a total value of about $5.4 million. Bhatt reported holding 17,044 shares of directly owned common stock after the transactions.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for SUPN.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.